RISKREVEAL

Serial Number 98892801
686

Registration Progress

Application Filed
Dec 9, 2024
Under Examination
Approved for Publication
Jul 1, 2025
Published for Opposition
Jul 1, 2025
Registered

Attorney Assistance

Notice of Publication
Due: Jul 31, 2025 13 days

Trademark Image

RISKREVEAL

Basic Information

Serial Number
98892801
Filing Date
December 9, 2024
Published for Opposition
July 1, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
686
Status Date
Jul 1, 2025
Application
Pending
Classes
044

Rights Holder

RAZOR GENOMICS, INC.

03
Address
110 10th Avenue, Suite 102, Room 123
Nashville, TN 37203

Ownership History

RAZOR GENOMICS, INC.

Original Applicant
03
Nashville, TN

RAZOR GENOMICS, INC.

Owner at Publication
03
Nashville, TN

Legal Representation

Attorney
DAVID R. STEVENS

USPTO Deadlines

Next Deadline
13 days remaining
Notice of Publication
Due Date
July 31, 2025
Extension Available
Until August 31, 2025
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

7 events
Date Code Type Description Documents
Jul 1, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jul 1, 2025 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jun 25, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
May 31, 2025 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
May 28, 2025 DOCK D ASSIGNED TO EXAMINER Loading...
May 19, 2025 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Dec 9, 2024 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 044
Medical testing for diagnostic or treatment purposes; Medical diagnostic testing for analysis of tumor tissue in the field of oncology; Medical molecular diagnostic testing for analysis of tumor tissue in the field of oncology; Medical prognostic testing for analysis of tumor tissue in the field of oncology; Medical molecular prognostic testing for analysis of tumor tissue in the field of oncology; Medical diagnostic molecular treatment stratification testing for analysis of tumor tissue in the field of oncology; Medical prognostic molecular treatment stratification testing for analysis of tumor tissue in the field of oncology; Medical testing of tumor tissue for use in risk segregation and managing disease treatment, namely, cancer.
First Use Anywhere: Feb 16, 2023
First Use in Commerce: Feb 16, 2023

Additional Information

Pseudo Mark
RISK REVEAL

Classification

International Classes
044